← FDA DRUG APPROVALS

FDA ANDA · ANDA091007

IMIPENEM AND CILASTATIN

Sponsor: HOSPIRA INC

APPLICATION
ANDA091007
TYPE
ANDA
ORIGINAL APPROVAL
2011-11-16
LATEST ACTION
2015-12-28
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

IMIPENEM AND CILASTATINDiscontinued
CILASTATIN SODIUM EQ 500MG BASE/VIAL, IMIPENEM 500MG/VIAL · POWDER · INTRAVENOUS

Approval history

2015-12-28Labeling · Supplement 1 · standardAP
2015-12-28Labeling · Supplement 6 · standardAP
2011-11-16OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →